Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.87B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.93M
Average 1.84M
IMVT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Immunovant, Inc.NASDAQ: IMVT
EBITDA · Q2 FY2027 · quarter ended Sep 2026
EBITDA remains negative
Q2 FY2027 EBITDA was -$97.16M, compared with -$125.8M a year earlier. Trailing-twelve-month EBITDA was -$509.88M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2026 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of $0 (+100.0%) for the fiscal year ending Mar 2027, a step up from the -22.4% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$97.16M+36.6% QoQ
- Last fiscal yearMar 2026
- -$504.98M-22.4% YoY
- LTMSep 2026
- -$509.88M-10.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +22.8% | +100.0% | +77.2 pp |
| 1 year | -22.4% | +100.0% | +122.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2026
- (504.98M) USD
- Year-over-year change
- -22.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (504.98M) | -22.4% |
| FY2025 | 2025-03-31 | (412.57M) | -59.6% |
| FY2024 | 2024-03-31 | (258.54M) | -30.4% |
| FY2023 | 2023-03-31 | (198.28M) | -26.5% |
| FY2022 | 2022-03-31 | (156.69M) | — |
EBITDA vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 EBITDA of -$509.88M is the lowest of the 11 companies compared; the peer median is -$137.86M.
- Its year-over-year change of -10.4% is the 6th highest of 11, against a peer median of -12.7%.
- EBITDA amounts to 7186.4% of revenue for IMVT, versus a peer median of 33.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $191.33M | +66.0% | — | 21.3% | |
| LTM Mar 2026 | $58.49M | +176.6% | — | 25.2% | |
| LTM Mar 2026 | $22.15M | +154.8% | — | 41.2% | |
| LTM Mar 2026 | -$70.61M | -31.5% | — | 843.9% | |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$171.58M | -48.1% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | -$178.45M | +0.1% | — | — |
| LTM Mar 2026 | -$193.41M | -17.1% | — | — | |
| LTM Mar 2026 | -$220.73M | -23.8% | — | — | |
| LTM Mar 2026 | -$408.44M | -151.5% | — | — | |
| LTM Sep 2026 | -$509.88M | -10.4% | — | 7186.4% | |
| Peer median (excluding IMVT) | -$137.86M | -12.7% | — | 33.2% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| Weighted Avg Shares | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
| Weighted Avg Shares (Diluted) | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.